HeartBeam Inc. Strengthens Cardiac Diagnostics with Two New U.S. Patents

HeartBeam Inc. (NASDAQ: BEAT), a leader in cardiac technology, has recently been granted two new U.S. patents, marking a significant milestone in the development of its proprietary 3D ECG platform. These patents not only expand the company's intellectual property portfolio but also underscore its commitment to advancing cardiac diagnostics. With over 20 U.S. and international patents already under its belt, HeartBeam is poised to revolutionize the way heart health is monitored and diagnosed.

The first patent covers a groundbreaking credit card-sized, cable-free 3D ECG device. This innovative device is designed to capture high-fidelity electrical signals from the chest and fingers in three noncoplanar directions, offering a portable solution for cardiac monitoring. The second patent pertains to a sophisticated rhythm analysis algorithm that continuously analyzes signal input, enhancing the accuracy and reliability of heart rhythm assessments. Together, these patents represent a leap forward in non-invasive cardiac diagnostics, providing patients and healthcare providers with powerful tools for early detection and management of heart conditions.

HeartBeam's advancements in cardiac technology are not just a win for the company but also for the broader medical community and patients worldwide. By enabling more precise and accessible heart health monitoring, these innovations have the potential to significantly improve outcomes for individuals at risk of or living with heart disease. For more information on HeartBeam's latest developments, visit https://ibn.fm/6xni4.